İsteğe bağlı ürün analizi
İzninizle, hangi araştırma yolculuklarının işe yaradığını anlamak için gizliliği gözeten sınırlı analizler kullanırız. Reklam izleyicileri veya oturum kaydı kullanmayız. Bu seçimi Tercihler bölümünden değiştirebilirsiniz. Okuyun Gizlilik Politikası.
Abbott Laboratories's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $183.8B | |
|---|---|---|
| Revenue (ttm) | 48.2B | |
| Net income (ttm) | 4.7B | |
| EPS (ttm) | $2.69 | |
| Shares out | 1.7B | |
| P/E (trailing) | 38.2x | |
| P/E (forward) | 17.9x | |
| Dividend | $2.52 (2.45%) | |
| Volume | 4,052,721 | |
| Beta | 0.58 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $43.08B | $43.65B | $40.11B | $41.95B | $44.33B | +0.7% |
| Gross profit | $23.21B | $22.32B | $20.04B | $21.33B | $24.61B | +1.5% |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | -1.1% |
| Net income | $7.07B | $6.93B | $5.72B | $13.40B | $6.52B | -2.0% |
| EPS (diluted) | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 | -1.4% |
| EBITDA | $12.16B | $11.89B | $10.61B | $10.83B | $11.55B | -1.3% |
| R&D | $2.74B | $2.89B | $2.74B | $2.84B | $2.94B | +1.8% |
| SG&A | $11.32B | $11.25B | $10.95B | $11.70B | $12.33B | +2.2% |
Recent company headlines from major financial publishers.
The base scenario assumes the FY2027 revenue and adjusted-EPS forecasts are achieved. It then assumes growth fades toward a mature-company pace; that post-FY2027 fade is a valuation premise, not a reported result.
Broader growth persistence would lift revenue, earnings, and cash beyond the period directly supported by dated forecasts.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.3% | $99.9 | $106 | $115 | $127 | $146 |
| 6.3% | $87.9 | $91.7 | $96.6 | $103 | $111 |
| 7.3% | $79.6 | $82.1 | $86.7 | $88.8 | $93.4 |
| 8.3% | $73.4 | $75.2 | $77.2 | $79.6 | $82.5 |
| 9.3% | $68.7 | $69.9 | $71.4 | $73.0 | $74.9 |
Upcoming earnings date and setup when available.
Her ay yayımlanan araştırma sürümünün taşıdığı derecelendirme. Bir derecelendirme, analiz tarihindeki fiyatı gerçeğe uygun değerle karşılaştırır; tahminin doğru çıkıp çıkmadığının kaydı değildir.
| Yıl | Oca | Şub | Mar | Nis | May | Haz | Tem | Ağu | Eyl | Eki | Kas | Ara |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
